Participant flow

A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. · Source last updated 2014-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received single doses of rituximab 750 milligrams per square meter (mg/m\^2) intravenously (IV) at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 grams per square meter (g/m\^2) IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.

   id

   FG000

   title

   Rituximab, Cytarabine, and Methotrexate (MTX)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Lack of Efficacy

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Administrative error

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Study terminated by Sponsor

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         5

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         5

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice